TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 39.2nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 51.3nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 53.4nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 86.1nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 139nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 147nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 161nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 183nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 263nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals
US Patent
Rhizen Pharmaceuticals
US Patent
Affinity DataIC50: 383nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair